{"id":"nafiverine","rwe":[{"pmid":"1127581","year":"1975","title":"Stability, absorption, excretion, and distribution of nafiverine.","finding":"","journal":"Journal of pharmaceutical sciences","studyType":"Clinical Study"},{"pmid":"6014089","year":"1966","title":"Structure-activity relationships in antispasmodic compounds chemically related to N,N'-Di-[alpha-(1-naphthyl)-propionyloxy-2-ethyl]-piperazine (Nafiverine).","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"},{"pmid":"4861934","year":"1966","title":"Toxicological investigation of N,N'-di-[alpha-(1-naphthyl)-propionyloxy-2-ethyl]-piperazine (Nafiverine) and its effects on some enzymes.","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"}],"tags":[{"label":"nafiverine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"naftidan","offLabel":[],"synonyms":["nafiverine","naftidan","naphiverine","nafiverine hydrochloride"],"timeline":[],"approvals":[],"brandName":"Naftidan","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"nafiverine","explanation":"Imagine your body's cells have locks on them, and nafiverine is a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that ultimately lead to a desired outcome, such as relieving a particular symptom or condition. This is a simplified explanation of how nafiverine is believed to work at a molecular level.","oneSentence":"Nafiverine is thought to work by interacting with a specific molecular target to produce a therapeutic effect.","technicalDetail":"Nafiverine is a selective antagonist of the muscarinic acetylcholine receptor M3, which plays a role in smooth muscle contraction and glandular secretion."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3790","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NAFIVERINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:52:57.357995","biosimilars":[],"competitors":[],"genericName":"nafiverine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"WLT400RC9Q","CHEBI":"CHEBI:135822","INN_ID":"1986","UMLSCUI":"C0068362","ChEMBL_ID":"CHEMBL2107421","PUBCHEM_CID":"21137","MESH_SUPPLEMENTAL_RECORD_UI":"C002681"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1975 Feb","pmid":"1127581","title":"Stability, absorption, excretion, and distribution of nafiverine.","journal":"Journal of pharmaceutical sciences"},{"date":"1966 Mar","pmid":"6014089","title":"Structure-activity relationships in antispasmodic compounds chemically related to N,N'-Di-[alpha-(1-naphthyl)-propionyloxy-2-ethyl]-piperazine (Nafiverine).","journal":"Arzneimittel-Forschung"},{"date":"1966 Mar","pmid":"4861934","title":"Toxicological investigation of N,N'-di-[alpha-(1-naphthyl)-propionyloxy-2-ethyl]-piperazine (Nafiverine) and its effects on some enzymes.","journal":"Arzneimittel-Forschung"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nafiverine is a small molecule drug in the nafiverine class, developed by an unknown original developer and currently owned by an unknown entity. Its target and exact mechanism of action are not specified. Nafiverine is not FDA-approved for any indications, and its commercial status, half-life, bioavailability, generic manufacturers, and off-patent status are unknown. As a result, there is limited information available on its safety profile and clinical use. Further research is needed to determine its potential therapeutic applications and risks.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}